E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 1.8 SEK 3.45% Market Closed
Market Cap: 436.9m SEK
Have any thoughts about
Enzymatica AB (publ)?
Write Note

Net Margin
Enzymatica AB (publ)

-122%
Current
-106%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-122%
=
Net Income
-54m
/
Revenue
44.2m

Net Margin Across Competitors

Country SE
Market Cap 436.9m SEK
Net Margin
-122%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 710.5B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 373.5B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country CH
Market Cap 202.7B CHF
Net Margin
20%
Country CH
Market Cap 183.3B CHF
Net Margin
35%
Country UK
Market Cap 162.4B GBP
Net Margin
13%
Country IE
Market Cap 146B USD
Net Margin
-126%
No Stocks Found

Enzymatica AB (publ)
Glance View

Market Cap
436.9m SEK
Industry
Pharmaceuticals

Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.

ENZY Intrinsic Value
1.83 SEK
Undervaluation 2%
Intrinsic Value
Price
E

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-122%
=
Net Income
-54m
/
Revenue
44.2m
What is the Net Margin of Enzymatica AB (publ)?

Based on Enzymatica AB (publ)'s most recent financial statements, the company has Net Margin of -122%.